NCT02022033View on ClinicalTrials.gov

BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 1, 2014

Primary Completion Date

July 23, 2019

Study Completion Date

March 17, 2022

Conditions
Pancreatic Cancer
Interventions
DRUG

FOLFOXA

"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"

Trial Locations (2)

02903

Roxanne Wood, Providence

The Miriam Hospital, Providence

Sponsors

Lead Sponsor

Brown University
All Listed Sponsors
lead

Brown University

OTHER